Samsung Biologics Co.,Ltd. (KRX:207940)
South Korea · Delayed Price · Currency is KRW 1,452,000
+30,000 (2.11%)
Nov 3, 2026, 3:30 PM KST
Samsung Biologics Employees
Samsung Biologics had 5,326 employees as of June 30, 2026. The number of employees increased by 279 or 5.53% compared to the same quarter last year. That makes Samsung Biologics the 5,405th largest employer in the world and 43rd in South Korea.
Employees
5,326
Change (1Y)
279
Growth (1Y)
5.53%
Revenue / Employee
961.55M KRW
Profits / Employee
372.57M KRW
Market Cap
67.14T
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 5,326 | 279 | 5.53% |
| Jun 30, 2025 | 5,047 | 303 | 6.39% |
| Dec 31, 2024 | 4,770 | 486 | 11.34% |
| Sep 30, 2024 | 4,744 | 460 | 10.74% |
| Sep 30, 2023 | 4,284 | - | - |
| Mar 31, 2023 | 4,296 | - | - |
| Mar 31, 2021 | 3,247 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Samsung Biologics News
- 13 days ago - Samsung Biologics Slides: Q3 2026 - Filings
- 2 months ago - Samsung Biologics Publishes PolyPeptide Offer Prospectus; Sets Tender Period - Nasdaq
- 3 months ago - Samsung Biologics Slides: Q2 2026 - Filings
- 3 months ago - Samsung Biologics Quarterly report: Q2 2026 - Filings
- 3 months ago - Samsung Biologics Delivers Solid Q2 2026 Growth, Operating Profit Rises - Nasdaq
- 3 months ago - PolyPeptide Receives CHF 1.46 Bln Samsung Offer, Posts Strong H1 Prelim. Result, Raises Guidance - Nasdaq
- 3 months ago - Samsung Biologics To Enter Peptide CDMO Market With CHF 1.46 Bln PolyPeptide Acquisition; Stock Down - Nasdaq
- 3 months ago - Samsung Biologics to acquire Switzerland's PolyPeptide Group in $1.8 billion all-cash deal - CNBC